A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

NCT06174766 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

324

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: HGP2102-1
DRUG: HGP2102-2
DRUG: RLD2209-1
DRUG: RLD2209-2

Sponsor

Hanmi Pharmaceutical Company Limited